Description

N1-(20-Amino-6,13,20-Triimino-5,7,12,14,19-Pentaazaicosan-1-Yl)-7,8-Dihydrobleomycinamide is a complex, semi-synthetic derivative of the bleomycin family of glycopeptide antibiotics. This compound is of significant interest in pharmaceutical research and development due to its potential as a key intermediate or active moiety in novel therapeutic agents. It is primarily utilized by research institutions and pharmaceutical companies engaged in the development of anti-cancer drugs and other specialized biologics. The compound, with CAS No. 11031-15-5, requires expert handling and high-purity synthesis to ensure research integrity and reproducible results.

Application

• Pharmaceutical Intermediate: Serves as a critical building block in the synthesis of novel bleomycin analogs and related glycopeptide-based therapeutics.
• Oncology Research: Used in biochemical and pharmacological studies to investigate mechanisms of DNA cleavage and cytotoxicity for cancer treatment development.
• Antibiotic Mechanism Studies: Employed as a reference standard or probe in research focused on the structure-activity relationships of bleomycin-family antibiotics.
• Bioconjugation: The reactive amine groups make it suitable for conjugation studies with other molecules, such as antibodies or targeting ligands, for drug delivery system development.
• Academic & Institutional Research: Utilized in university and government laboratories for fundamental research in medicinal chemistry and molecular biology.
• Process Development: Acts as a standard in the development and validation of analytical methods (e.g., HPLC, MS) for quality control in API manufacturing.

Basic Information

Product Name	N1-(20-Amino-6,13,20-Triimino-5,7,12,14,19-Pentaazaicosan-1-Yl)-7,8-Dihydrobleomycinamide
CAS No.	11031-15-5
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	7,8-Dihydrobleomycinamide, N1-[20-Amino-6,13,20-triimino-5,7,12,14,19-pentaazaicosan-1-yl]-; Bleomycin derivative; BLM derivative; Pentaazaicosan derivative; Research Compound 11031-15-5; Antibiotic intermediate; Glycopeptide intermediate
EINECS	Contact for details

Quality Control

Our N1-(20-Amino-6,13,20-Triimino-5,7,12,14,19-Pentaazaicosan-1-Yl)-7,8-Dihydrobleomycinamide is produced under strict quality management protocols suitable for research and development applications. Each batch undergoes comprehensive analytical characterization to ensure identity, purity, and consistency. Certificates of Analysis (COA) detailing purity (by HPLC), identity confirmation (by spectroscopic methods), and other critical parameters are provided with every shipment. We support cGMP-compliant documentation for advanced pharmaceutical development needs.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as indicated on the label. This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccants or inert atmosphere to maintain stability.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 95.0%
Water Content (KF)	≤ 5.0%
Related Substances (HPLC)	Individual impurity ≤ 2.0%; Total impurities ≤ 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.